Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16247
Title: Immunotherapeutic strategies in antiphospholipid syndrome
Austin Authors: Hoi, Alberta Y ;Ross, Laura;Day, Jessica;Buchanan, Russell R C 
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Rheumatology, Austin Health, Heidelberg, Victoria, Australia
Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia
School of Clinical Sciences, Monash University, Victoria, Australia
Issue Date: Mar-2017
metadata.dc.date: 2016-08-30
Publication information: Internal Medicine Journal 2016; 47(3): 250-256
Abstract: Antiphospholipid syndrome (APS) is an autoimmune condition, characterized by the persistent presence of antiphospholipid antibodies (aPL) and either thrombosis or obstetric morbidity. The cornerstone of therapy is long-term anticoagulation to reduce morbidity and mortality; however, better understanding of the immunological pathways may direct us to develop future therapeutic strategies. We provide an overview of the current understanding of the immunopathogenesis of this perplexing condition and its associated morbidities and current evidence for some of the immunotherapeutic strategies.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16247
DOI: 10.1111/imj.13245
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27572264
Type: Journal Article
Subjects: CAPS
antiphospholipid syndrome
therapeutic options
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Dec 4, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.